Figure 5 | British Journal of Cancer

Figure 5

From: Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis

Figure 5

Overall survival analysis in exon 19 deletion tumours. (A) OS analysis in exon 19 deletion tumours receiving reversible and irreversible TKIs. Pooled analysis showed significant OS benefits only with irreversible TKIs. (B) OS analysis in exon 19 deletion tumours receiving cisplatin- and carboplatin-based chemotherapy. Pooled analysis showed significant OS benefit towards TKI treatment in cisplatin-based chemotherapy only. Squares indicate study-specific HRs (size of the square reflects the study-specific statistical weight); horizontal lines indicate 95% CI; diamond indicates the summary HR estimate with its 95% CI.

Back to article page